{"disease":{"id":"prodromal-alzheimer-s-disease","name":"prodromal alzheimer s disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06033066","title":"Financial Incentives and Recruitment to the APT Webstudy","phase":"NA","overall_status":"COMPLETED","enrollment_count":44844,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT01953601","title":"Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1454,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06957418","title":"Alzheimer's Tau Platform: Master Protocol","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":900,"lead_sponsor_name":"Paul S. Aisen","has_results":false},{"nct_id":"NCT07167966","title":"Alzheimer's Tau Platform: Regimen A - AADvac1","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Paul S. Aisen","has_results":false},{"nct_id":"NCT04004767","title":"TRC-PAD Program: In-Clinic Trial-Ready Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT05934188","title":"Exploring the Gut-Brain Axis in Ageing and Neurodegeneration","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"IRCCS San Camillo, Venezia, Italy","has_results":false},{"nct_id":"NCT03486938","title":"Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"AgeneBio","has_results":true},{"nct_id":"NCT04828122","title":"Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech","phase":"","overall_status":"COMPLETED","enrollment_count":141,"lead_sponsor_name":"Novoic Limited","has_results":false},{"nct_id":"NCT03234686","title":"Deferiprone to Delay Dementia (The 3D Study)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Neuroscience Trials Australia","has_results":false},{"nct_id":"NCT06956300","title":"TMS for Cognitive Decline in Aging and Preclinical AD","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT04851496","title":"Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Novoic Limited","has_results":false},{"nct_id":"NCT04846426","title":"Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension","phase":"","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"Novoic Limited","has_results":false},{"nct_id":"NCT04928976","title":"Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Novoic Limited","has_results":false},{"nct_id":"NCT04951284","title":"Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension","phase":"","overall_status":"TERMINATED","enrollment_count":42,"lead_sponsor_name":"Novoic Limited","has_results":false},{"nct_id":"NCT04937959","title":"Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Novoic Limited","has_results":false},{"nct_id":"NCT04240665","title":"The Digital Memory Notebook","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":20,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT02910739","title":"An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}